REG - Arecor Therapeutics - Notice of FY25 Results

Arecor TherapeuticsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260330:nRSd5104Ya&default-theme=true

RNS Number : 5104Y  Arecor Therapeutics PLC  30 March 2026

 

Arecor Therapeutics plc

("Arecor" or the "Company")

 

Notice of FY25 Results

Cambridge, UK, 30 March 2026: Arecor Therapeutics plc (AIM: AREC), a clinical
stage biotech company developing superior therapeutics that can reduce
treatment burden and improve outcomes for people living with diabetes, obesity
and other cardiometabolic diseases, will announce its full year results for
the twelve months ended 31 December 2025 on Monday 13 April 2026.

Dr Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial
Officer, will host a webcast and Q&A for analysts and institutional
investors at 9.30am UK time on Monday 13 April 2026. To register, please
contact arecor@vigoconsulting.com.

For private investors, there will be a presentation via the Investor Meet
Company (https://www.investormeetcompany.com/) platform at 11.00am UK time on
Thursday 23 April 2026. To register, please see
https://www.investormeetcompany.com/companies/arecor-therapeutics-plc
(https://www.investormeetcompany.com/companies/arecor-therapeutics-plc) .

Questions can be submitted pre-event via the Investor Meet Company dashboard
up until 9.00am UK time on 22 Apr 2026 or during the live presentation.
Investors who follow Arecor on the Investor Meet Company platform will
automatically be invited.

A copy of the full year results presentation will be released on the Company
website at https://arecor.com/investor-centre/financial-information/
(https://arecor.com/investor-centre/financial-information/) after the meeting
on 13 April 2026.

-ENDS-

For more information, please contact:

 Arecor Therapeutics plc

Dr Sarah Howell, Chief Executive Officer

David Ellam, Chief Financial Officer            +44 (0) 1223 426060

                                                  info@arecor.com
 Singer Capital Markets Advisory LLP

(NOMAD and Broker)

 Phil Davies, James Fischer                       +44 (0) 20 7496 3000
 Vigo Consulting (Financial Communications)       +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris

                                                  arecor@vigoconsulting.com
 Vida Strategic Partners (US Investor Relations)  +1 (415) 675-7401

 Stephanie Diaz                                   sdiaz@vidasp.com

 

Notes to Editors

About Arecor

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company
developing superior therapeutics that can reduce treatment burden and improve
outcomes for people living with diabetes, obesity and other cardiometabolic
diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL)
ultra-rapid-acting insulin in development. Arecor has signed an initial
strategic partnership with Sequel Med Tech, a leading automated insulin
delivery (AID) system company to co-develop AT278 in combination with Sequel's
twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID
systems, addressing a multi-billion dollar diabetes market. Arecor is also
developing a novel oral delivery platform for peptides with GLP-1 receptor
agonists its first validation target.

The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For
further details please see www.arecor.com (http://www.arecor.com/) .

Arecor® and Arestat® are registered trademarks of Arecor Limited.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUBUNRNUUOUAR



            Copyright 2019 Regulatory News Service, all rights reserved